Follicular Lymphoma
News
Obinutuzumab approved to treat FL
The European Commission (EC) has approved the use of obinutuzumab (Gazyvaro), an anti-CD20 monoclonal antibody, in patients with follicular...
News
Follicular lymphoma with histologic transformation may merit ASCT
Key clinical point: Histologic transformation of follicular lymphoma tends to occur early and may merit intensive salvage with autologous stem...
Conference Coverage
Dr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016
News
Enzastaurin flops as maintenance in treated DLBCL
Key clinical point: The experimental agent enzastaurin was no better than placebo as maintenance therapy in patients who had achieved a complete...
News
Study links radon and hematologic cancers in women
New research suggests there is a significant positive association between high levels of residential radon and the risk of hematologic...
News
CHMP recommends approving drug to treat FL
The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that obinutuzumab (Gazyvaro), an anti-CD20...
News
Low transformation rate in nodular lymphocyte–predominant Hodgkin lymphoma
Key clinical point: The risk of transformation to diffuse large B-cell lymphoma is low in patients with nodular lymphocyte–predominant Hodgkin...
Conference Coverage
Treatment can produce durable responses in NHL
2016 AACR Annual Meeting © AACR/Todd Buchanan NEW ORLEANS—Administering an antibody-radionuclide conjugate after B-cell depletion with rituximab...
Conference Coverage
Drug shows early promise for low-grade lymphoma
follicular lymphoma NEW ORLEANS—The TLR9 agonist SD-101 has produced encouraging early results in patients with low-grade B-cell lymphoma,...
News
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myeloma
Key clinical point: The CUDC-907 dose to be used in phase II studies will be 60 mg on a 5-days-on/2-days-off dosing schedule. Major finding: Two...
News
Dual inhibitor shows early promise for DLBCL
The small-molecule inhibitor CUDC-907 can provide disease control in patients with relapsed or refractory lymphoma and multiple myeloma (MM),...